Actively Recruiting
Evaluating Nalbuphine Extended-Release Tablets Versus Placebo to Treat Chronic Cough in Idiopathic Pulmonary Fibrosis
Led by Trevi Therapeutics · Updated on 2026-10-09
201
Participants Needed
4
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of Nalbuphine Extended-Release NAL ER tablets for treating chronic cough in people with Idiopathic Pulmonary Fibrosis IPF. This Phase 3 study aims to compare NAL ER with a placebo to better understand its impact on cough frequency and severity in this condition. Participants will first complete a 2-week blinded dose adjustment period, then continue with a fixed dose of NAL ER 54 mg twice daily or a matching placebo for 12 weeks. The study is randomized and double-blind, meaning neither the participants nor the researchers know who receives the active drug or placebo during the trial. During the study, participants will be monitored for changes in 24-hour cough frequency, cough severity, respiratory symptoms, quality of life, and patient-reported impressions. Safety will be assessed by tracking any adverse events through Week 17. The total participation duration includes the 14-week treatment and follow-up period to evaluate both efficacy and safety outcomes.
CONDITIONS
Brief Title
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets
Research Team
P
Paula Buckley
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here